Spotlight on Gynecology/Obstetrics

Credits: 1.00 CME
Incorporating Recently Approved Targeted Agents, Emerging Combinations, and Genetic Testing for the Optimal Management of Patients with Ovarian Cancer
Thomas Herzog, MD
University of Nebraska Medical Center

Incorporating Recently Approved Targeted Agents, Emerging Combinations, and Genetic Testing for the Optimal Management of Patients with Ovarian Cancer

Start

Activity Details

Free CME
1 AMA PRA Category 1 Credit(s)
Released: June 18, 2020
Expires: April 18, 2021
60 minutes to complete

Accredited By

The University of Nebraska Medical Center, Center for Continuing Education

Target Audience

The target audience for this activity is gynecologic oncologists, medical oncologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with gynecologic malignancies.

Learning Objectives

After participating in this activity, participants should be better able to:

  • Assess the efficacy and safety of PARP inhibitors or their combinations in the maintenance and treatment setting for the management of patients with ovarian cancer
  • Evaluate the various genetic testing platforms and their utility in identifying appropriate patients for platinum-based therapy and PARP inhibitor therapy
  • Develop strategies for the optimal utilization of PARP inhibitors when managing patients with ovarian cancer
  • Review novel agents that are under investigation for the treatment of platinum-resistant ovarian cancer

Activity Description

This activity will provide expert guidance regarding the use of currently-available therapies and companion diagnostics and will help clinicians plan for the optimal integration of new indications and combinations into practice when they become available.

Statement of Educational Need

Considering the volume of research regarding the use of PARP inhibitors for patients with ovarian cancer, clinicians are challenged to evaluate and interpret the clinical significance of emerging data, both scientific and clinical. Thus, clinicians treating patients with ovarian cancer need expert guidance to evaluate emerging scientific and clinical data, use existing PARP inhibitors safely and effectively, and plan strategies to appropriately integrate new indications and combinations into practice when they become available, in consideration of patient needs and preferences.

Agenda

  • Currently Available Systemic and Maintenance Therapies and Emerging Combinations for the Treatment of Ovarian Cancer
  • Integrating Genetic Testing Into Clinical Practice
  • Real-World Use of Poly ADP Ribose Polymerase Inhibitors (PARPi): Case-Based Discussion
  • Summary

 

Faculty

Thomas Herzog, MD
Deputy Director, University of Cincinnati Cancer Institute
Paul & Carolyn Flory Professor, Vice-Chair of Quality & Safety
Department of Obstetrics & Gynecology
University of Cincinnati
Cincinnati, Ohio

Disclosures
Advisory Boards: AstraZeneca, Caris Life Sciences, Clovis Oncology, F. Hoffman-La Roche, Tesaro, Inc.


Conflict of Interest Policy/Disclosure Statement

Faculty and Planning Committee Disclosures

As a provider accredited by ACCME, the UNMC Center for Continuing Education must ensure balance, objectivity, independence, and scientific rigor in its educational activities. Presenters are encouraged to provide a balanced view of therapeutic options by utilizing either generic names or the trade names of several to ensure impartiality.

All presenters, planners, and others in a position to control continuing medical education content participating in a UNMC Center for Continuing Education activity are required to disclose relationships with commercial interests. A commercial interest is any entity producing, marketing, reselling, or distributing health care goods or services consumed by, or used on, patients. Disclosure of these commitments and/or relationships is included in activity materials so that participants in the activity may formulate their own judgments in interpreting its content and evaluating its recommendations.

This activity may include presentations in which presenters may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications.

All materials are included with the permission of the authors. The opinions expressed are those of the authors and are not to be construed as those of the UNMC Center for Continuing Education or Bio Ascend. The information presented in this activity is not meant to serve as a guideline for patient management; primary references, relevant practice guidelines, and full prescribing information should be consulted.

The faculty and planning committee members for this activity have no conflicts to disclose with the exception of those listed on the following presenter slide. All disclosed conflicts of interest have been resolved by independent content review.

Accreditation Statement

Continuing Education

The University of Nebraska Medical Center (UNMC) Center for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. 

The UNMC Center for Continuing Education designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the ACCME through the joint providership of the UNMC Center for Continuing Education and Bio Ascend.

Instructions for Receiving Credit

There are no fees for participating and receiving credit for this activity. During the accredited period, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) complete the pre- and post-activity assessments and evaluation.

Participants who complete the educational activity, pre- and post-activity assessments, and evaluation will receive a certificate of credit.

Materials will be available online through April 18, 2021.

Statement of Commercial Support

This activity is supported by independent educational grants from AstraZeneca, Clovis Oncology, and Tesaro, a GSK Company.

Disclaimer Statement/Disclosure of Unlabeled Use

UNMC CCE and Bio Ascend do not recommend the use of any agent outside of the labeled indication. The opinions expressed in the educational activity do not necessarily represent the views of UNMC CCE and Bio Ascend.

Contact Information for Questions About the Activity

cme@bioascend.com

Activity Details

Free CME
1 AMA PRA Category 1 Credit(s)
Released: June 18, 2020
Expires: April 18, 2021
60 minutes to complete

Accredited By

The University of Nebraska Medical Center, Center for Continuing Education

Target Audience

The target audience for this activity is gynecologic oncologists, medical oncologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with gynecologic malignancies.

Learning Objectives

After participating in this activity, participants should be better able to:

  • Assess the efficacy and safety of PARP inhibitors or their combinations in the maintenance and treatment setting for the management of patients with ovarian cancer
  • Evaluate the various genetic testing platforms and their utility in identifying appropriate patients for platinum-based therapy and PARP inhibitor therapy
  • Develop strategies for the optimal utilization of PARP inhibitors when managing patients with ovarian cancer
  • Review novel agents that are under investigation for the treatment of platinum-resistant ovarian cancer

Activity Description

This activity will provide expert guidance regarding the use of currently-available therapies and companion diagnostics and will help clinicians plan for the optimal integration of new indications and combinations into practice when they become available.

Statement of Educational Need

Considering the volume of research regarding the use of PARP inhibitors for patients with ovarian cancer, clinicians are challenged to evaluate and interpret the clinical significance of emerging data, both scientific and clinical. Thus, clinicians treating patients with ovarian cancer need expert guidance to evaluate emerging scientific and clinical data, use existing PARP inhibitors safely and effectively, and plan strategies to appropriately integrate new indications and combinations into practice when they become available, in consideration of patient needs and preferences.

Agenda

  • Currently Available Systemic and Maintenance Therapies and Emerging Combinations for the Treatment of Ovarian Cancer
  • Integrating Genetic Testing Into Clinical Practice
  • Real-World Use of Poly ADP Ribose Polymerase Inhibitors (PARPi): Case-Based Discussion
  • Summary

 

Faculty

Thomas Herzog, MD
Deputy Director, University of Cincinnati Cancer Institute
Paul & Carolyn Flory Professor, Vice-Chair of Quality & Safety
Department of Obstetrics & Gynecology
University of Cincinnati
Cincinnati, Ohio

Disclosures
Advisory Boards: AstraZeneca, Caris Life Sciences, Clovis Oncology, F. Hoffman-La Roche, Tesaro, Inc.


Conflict of Interest Policy/Disclosure Statement

Faculty and Planning Committee Disclosures

As a provider accredited by ACCME, the UNMC Center for Continuing Education must ensure balance, objectivity, independence, and scientific rigor in its educational activities. Presenters are encouraged to provide a balanced view of therapeutic options by utilizing either generic names or the trade names of several to ensure impartiality.

All presenters, planners, and others in a position to control continuing medical education content participating in a UNMC Center for Continuing Education activity are required to disclose relationships with commercial interests. A commercial interest is any entity producing, marketing, reselling, or distributing health care goods or services consumed by, or used on, patients. Disclosure of these commitments and/or relationships is included in activity materials so that participants in the activity may formulate their own judgments in interpreting its content and evaluating its recommendations.

This activity may include presentations in which presenters may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications.

All materials are included with the permission of the authors. The opinions expressed are those of the authors and are not to be construed as those of the UNMC Center for Continuing Education or Bio Ascend. The information presented in this activity is not meant to serve as a guideline for patient management; primary references, relevant practice guidelines, and full prescribing information should be consulted.

The faculty and planning committee members for this activity have no conflicts to disclose with the exception of those listed on the following presenter slide. All disclosed conflicts of interest have been resolved by independent content review.

Accreditation Statement

Continuing Education

The University of Nebraska Medical Center (UNMC) Center for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. 

The UNMC Center for Continuing Education designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the ACCME through the joint providership of the UNMC Center for Continuing Education and Bio Ascend.

Instructions for Receiving Credit

There are no fees for participating and receiving credit for this activity. During the accredited period, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) complete the pre- and post-activity assessments and evaluation.

Participants who complete the educational activity, pre- and post-activity assessments, and evaluation will receive a certificate of credit.

Materials will be available online through April 18, 2021.

Statement of Commercial Support

This activity is supported by independent educational grants from AstraZeneca, Clovis Oncology, and Tesaro, a GSK Company.

Disclaimer Statement/Disclosure of Unlabeled Use

UNMC CCE and Bio Ascend do not recommend the use of any agent outside of the labeled indication. The opinions expressed in the educational activity do not necessarily represent the views of UNMC CCE and Bio Ascend.

Contact Information for Questions About the Activity

cme@bioascend.com

Gynecology/Obstetrics Presentations

1.00 CME
University of Nebraska Medical Center
Incorporating Recently Approved Targeted Agents, Emerging Combinations, and Genetic Testing for the Optimal Management of Patients with Ovarian Cancer

Incorporating Recently Approved Targeted Agents, Emerging Combinations, and Genetic Testing for the Optimal Management of Patients with Ovarian Cancer

Start

Activity Details

Free CME
1 AMA PRA Category 1 Credit(s)
Released: June 18, 2020
Expires: April 18, 2021
60 minutes to complete

Accredited By

The University of Nebraska Medical Center, Center for Continuing Education

Target Audience

The target audience for this activity is gynecologic oncologists, medical oncologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with gynecologic malignancies.

Learning Objectives

After participating in this activity, participants should be better able to:

  • Assess the efficacy and safety of PARP inhibitors or their combinations in the maintenance and treatment setting for the management of patients with ovarian cancer
  • Evaluate the various genetic testing platforms and their utility in identifying appropriate patients for platinum-based therapy and PARP inhibitor therapy
  • Develop strategies for the optimal utilization of PARP inhibitors when managing patients with ovarian cancer
  • Review novel agents that are under investigation for the treatment of platinum-resistant ovarian cancer

Activity Description

This activity will provide expert guidance regarding the use of currently-available therapies and companion diagnostics and will help clinicians plan for the optimal integration of new indications and combinations into practice when they become available.

Statement of Educational Need

Considering the volume of research regarding the use of PARP inhibitors for patients with ovarian cancer, clinicians are challenged to evaluate and interpret the clinical significance of emerging data, both scientific and clinical. Thus, clinicians treating patients with ovarian cancer need expert guidance to evaluate emerging scientific and clinical data, use existing PARP inhibitors safely and effectively, and plan strategies to appropriately integrate new indications and combinations into practice when they become available, in consideration of patient needs and preferences.

Agenda

  • Currently Available Systemic and Maintenance Therapies and Emerging Combinations for the Treatment of Ovarian Cancer
  • Integrating Genetic Testing Into Clinical Practice
  • Real-World Use of Poly ADP Ribose Polymerase Inhibitors (PARPi): Case-Based Discussion
  • Summary

 

Faculty

Thomas Herzog, MD
Deputy Director, University of Cincinnati Cancer Institute
Paul & Carolyn Flory Professor, Vice-Chair of Quality & Safety
Department of Obstetrics & Gynecology
University of Cincinnati
Cincinnati, Ohio

Disclosures
Advisory Boards: AstraZeneca, Caris Life Sciences, Clovis Oncology, F. Hoffman-La Roche, Tesaro, Inc.


Conflict of Interest Policy/Disclosure Statement

Faculty and Planning Committee Disclosures

As a provider accredited by ACCME, the UNMC Center for Continuing Education must ensure balance, objectivity, independence, and scientific rigor in its educational activities. Presenters are encouraged to provide a balanced view of therapeutic options by utilizing either generic names or the trade names of several to ensure impartiality.

All presenters, planners, and others in a position to control continuing medical education content participating in a UNMC Center for Continuing Education activity are required to disclose relationships with commercial interests. A commercial interest is any entity producing, marketing, reselling, or distributing health care goods or services consumed by, or used on, patients. Disclosure of these commitments and/or relationships is included in activity materials so that participants in the activity may formulate their own judgments in interpreting its content and evaluating its recommendations.

This activity may include presentations in which presenters may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications.

All materials are included with the permission of the authors. The opinions expressed are those of the authors and are not to be construed as those of the UNMC Center for Continuing Education or Bio Ascend. The information presented in this activity is not meant to serve as a guideline for patient management; primary references, relevant practice guidelines, and full prescribing information should be consulted.

The faculty and planning committee members for this activity have no conflicts to disclose with the exception of those listed on the following presenter slide. All disclosed conflicts of interest have been resolved by independent content review.

Accreditation Statement

Continuing Education

The University of Nebraska Medical Center (UNMC) Center for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. 

The UNMC Center for Continuing Education designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the ACCME through the joint providership of the UNMC Center for Continuing Education and Bio Ascend.

Instructions for Receiving Credit

There are no fees for participating and receiving credit for this activity. During the accredited period, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) complete the pre- and post-activity assessments and evaluation.

Participants who complete the educational activity, pre- and post-activity assessments, and evaluation will receive a certificate of credit.

Materials will be available online through April 18, 2021.

Statement of Commercial Support

This activity is supported by independent educational grants from AstraZeneca, Clovis Oncology, and Tesaro, a GSK Company.

Disclaimer Statement/Disclosure of Unlabeled Use

UNMC CCE and Bio Ascend do not recommend the use of any agent outside of the labeled indication. The opinions expressed in the educational activity do not necessarily represent the views of UNMC CCE and Bio Ascend.

Contact Information for Questions About the Activity

cme@bioascend.com

Activity Details

Free CME
1 AMA PRA Category 1 Credit(s)
Released: June 18, 2020
Expires: April 18, 2021
60 minutes to complete

Accredited By

The University of Nebraska Medical Center, Center for Continuing Education

Target Audience

The target audience for this activity is gynecologic oncologists, medical oncologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with gynecologic malignancies.

Learning Objectives

After participating in this activity, participants should be better able to:

  • Assess the efficacy and safety of PARP inhibitors or their combinations in the maintenance and treatment setting for the management of patients with ovarian cancer
  • Evaluate the various genetic testing platforms and their utility in identifying appropriate patients for platinum-based therapy and PARP inhibitor therapy
  • Develop strategies for the optimal utilization of PARP inhibitors when managing patients with ovarian cancer
  • Review novel agents that are under investigation for the treatment of platinum-resistant ovarian cancer

Activity Description

This activity will provide expert guidance regarding the use of currently-available therapies and companion diagnostics and will help clinicians plan for the optimal integration of new indications and combinations into practice when they become available.

Statement of Educational Need

Considering the volume of research regarding the use of PARP inhibitors for patients with ovarian cancer, clinicians are challenged to evaluate and interpret the clinical significance of emerging data, both scientific and clinical. Thus, clinicians treating patients with ovarian cancer need expert guidance to evaluate emerging scientific and clinical data, use existing PARP inhibitors safely and effectively, and plan strategies to appropriately integrate new indications and combinations into practice when they become available, in consideration of patient needs and preferences.

Agenda

  • Currently Available Systemic and Maintenance Therapies and Emerging Combinations for the Treatment of Ovarian Cancer
  • Integrating Genetic Testing Into Clinical Practice
  • Real-World Use of Poly ADP Ribose Polymerase Inhibitors (PARPi): Case-Based Discussion
  • Summary

 

Faculty

Thomas Herzog, MD
Deputy Director, University of Cincinnati Cancer Institute
Paul & Carolyn Flory Professor, Vice-Chair of Quality & Safety
Department of Obstetrics & Gynecology
University of Cincinnati
Cincinnati, Ohio

Disclosures
Advisory Boards: AstraZeneca, Caris Life Sciences, Clovis Oncology, F. Hoffman-La Roche, Tesaro, Inc.


Conflict of Interest Policy/Disclosure Statement

Faculty and Planning Committee Disclosures

As a provider accredited by ACCME, the UNMC Center for Continuing Education must ensure balance, objectivity, independence, and scientific rigor in its educational activities. Presenters are encouraged to provide a balanced view of therapeutic options by utilizing either generic names or the trade names of several to ensure impartiality.

All presenters, planners, and others in a position to control continuing medical education content participating in a UNMC Center for Continuing Education activity are required to disclose relationships with commercial interests. A commercial interest is any entity producing, marketing, reselling, or distributing health care goods or services consumed by, or used on, patients. Disclosure of these commitments and/or relationships is included in activity materials so that participants in the activity may formulate their own judgments in interpreting its content and evaluating its recommendations.

This activity may include presentations in which presenters may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications.

All materials are included with the permission of the authors. The opinions expressed are those of the authors and are not to be construed as those of the UNMC Center for Continuing Education or Bio Ascend. The information presented in this activity is not meant to serve as a guideline for patient management; primary references, relevant practice guidelines, and full prescribing information should be consulted.

The faculty and planning committee members for this activity have no conflicts to disclose with the exception of those listed on the following presenter slide. All disclosed conflicts of interest have been resolved by independent content review.

Accreditation Statement

Continuing Education

The University of Nebraska Medical Center (UNMC) Center for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. 

The UNMC Center for Continuing Education designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the ACCME through the joint providership of the UNMC Center for Continuing Education and Bio Ascend.

Instructions for Receiving Credit

There are no fees for participating and receiving credit for this activity. During the accredited period, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) complete the pre- and post-activity assessments and evaluation.

Participants who complete the educational activity, pre- and post-activity assessments, and evaluation will receive a certificate of credit.

Materials will be available online through April 18, 2021.

Statement of Commercial Support

This activity is supported by independent educational grants from AstraZeneca, Clovis Oncology, and Tesaro, a GSK Company.

Disclaimer Statement/Disclosure of Unlabeled Use

UNMC CCE and Bio Ascend do not recommend the use of any agent outside of the labeled indication. The opinions expressed in the educational activity do not necessarily represent the views of UNMC CCE and Bio Ascend.

Contact Information for Questions About the Activity

cme@bioascend.com

0.75 CME / CNE
Forefront Collaborative
HER Disease, Shared Perspectives: A multi-disciplinary discussion on HR+, HER2- metastatic breast cancer treatment options

HER Disease, Shared Perspectives: A multi-disciplinary discussion on HR+, HER2- metastatic breast cancer treatment options

Start

Activity Details

Free CME/CNE
0.75 AMA PRA Category 1 Credit(s)
0.75 Contact Hour(s)
Released: December 16, 2019
Expires: December 16, 2020
45 minutes to complete

Accredited By

 

Target Audience

Medical oncologists, community oncologists, nurse practitioners, and physician assistants. Other healthcare professionals including radiation oncologists, primary care physicians, pharmacists, and nurses who treat patients with HR+, HER2- metastatic breast cancer (mBC) may also benefit from participation in the educational activity. 

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Evaluate and apply emerging clinical data and evolving strategies for the treatment of metastatic breast cancer to optimize the outcomes of individual patients.
  • Analyze patient and disease characteristics that influence treatment selection for patients with HR+, HER2- metastatic breast cancer.

Activity Description

The treatment landscape for HR+, HER2- metastatic breast cancer has gone through a paradigm shift in treatment, with the advent of targeted therapies. From emerging clinical data to treatment selection, a multidisciplinary panel led by Hope Rugo, MD, FASCO, team up with Vandana Abramson, MD, Erika Hamilton, MD, and Lauren Czapla, NP, to provide a practical update for practicing clinicians on key treatment advances, and analyzing patient and disease characteristics influencing treatment selection for patients with HR+, HER2- metastatic breast cancer.

Statement of Educational Need

With the recent approvals, and new clinical data, medical oncologists, nurse practitioners, and physician assistants are faced with three challenges:
  • Staying abreast of the rapidly expanding evidence base to inform treatment of HR+, HER2- metastatic breast cancer (knowledge-based gaps).
  • Interpreting emerging data of approved and investigational therapies to best guide clinical decision making (competency-based gaps).
  • Analyzing patient and disease characteristics that inform treatment selection for a patient with HR+, HER2- metastatic breast cancer.

Agenda

  • Overview of HR+, HER2- emerging targeted therapies.
  • Tumor–board-style discussion of a patient with HR+, HER2- metastatic breast cancer.
  • Visual guide for treatment selection (algorithm) for HR +, HER2- metastatic breast cancer.

Faculty

Hope S. Rugo, MD, FASCO
Professor of Medicine,
Director, Breast Oncology and Clinical Trials Education
Helen Diller Family Comprehensive Cancer Center
University of California, San Francisco
San Francisco, California


Vandana G. Abramson, MD, MTR
Associate Professor of Medicine,
Division of Hematology-Oncology
Vanderbilt University Medical Center
Nashville, Tennessee


Erika P. Hamilton, MD
Director, Breast and Gynecologic Cancer Program
Sarah Cannon Research Institute/Tennessee Oncology
Nashville, Tennessee


Lauren E. Czapla, RN, MS, WHNP-BC, AOCNP
Nurse Practitioner,
Breast Oncology
Oncofertility Program
Dana-Farber Cancer Institute
Boston, Massachusetts


Conflict of Interest Policy/Disclosure Statement

Disclosure Statement
Educational activities provided by Forefront Collaborative must demonstrate balance, independence, and scientific rigor. All those in a position to control the content of an activity must disclose all relevant financial relationship(s) with commercial interest(s). The disclosures will be listed in the activity handout.

Disclosure and Conflict of Interest Resolution
Educational activities provided by Forefront Collaborative must demonstrate balance, independence, and scientific rigor. All those in a position to control the content of an activity must disclose all relevant financial relationship(s) with commercial interest(s)*. For this educational activity, all conflicts of interest have been resolved through peer review and revisions to ensure independence, evidence base, fair balance, and absence of commercial bias. Disclosures appear below.

*The ACCME defines a commercial interest as any entity producing, marketing, reselling, or distributing health care goods or services consumed by or used on patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests – unless the provider of clinical service is owned, or controlled by, an ACCME-defined commercial interest.

The following individuals have indicated that neither they nor their spouses/partners have had, in the past 12 months, financial relationship(s) with commercial interests relative to the content of this CME activity:
  • Planners (Forefront Collaborative):
    Megan Ragan
  • Faculty:
    Lauren E. Czapla, RN, MS, WHNP-BC, AOCNP
The following individuals have disclosed that they and/or their spouse/partner has had a financial relationship in the past 12 months:
  • Faculty:
    Hope S. Rugo, MD, FASCO
    Contracted research—Pfizer, Merck, Novartis, Lilly, Genentech, OBI, Odonate, Daiichi-Sankyo, Eisai, Seattle Genetics, MacroGenics, and Immunomedics (all funding to UC Regents)
    Travel support to academic meetings—Daiichi-Sankyo, Mylan, Pfizer, Amgen, Merck, AstraZeneca, MacroGenics, and Puma

    Erika P. Hamilton, MD
    Consultant—Pfizer (institutional compensation, not personal), Cascadian Therapeutics, and Lilly (institutional compensation only, not personal)
    Speakers bureau—Genentech/Roche (institutional compensation only, not personal)
    Advisory board—Lilly (institutional compensation only, not personal)
    Contracted research—Lilly, Pfizer, Genentech/Roche, Hutchison MediPharma, OncoMed, MedImmune, Stemcentrx, AbbVie, Curis, Verastem, Zymeworks, Syndax, Lycra, Rgenix, Novartis, Mersana, TapImmune, BerGenBio, Tesaro, Medivation, Kadmon, Boehringer Ingelheim, Eisai, H3 Biomedicine, Radius Health, Acerta, Takeda, MacroGenics, Immunomedics, Fujifilm, Effector, Syros, Unum, Sutro, Aravive, Deciphera, Clovis, and Sermonix

    Vandana G. Abramson, MD, MTR
    Advisory board—Novartis
    Contracted research—Novartis and Genentech

  • Planners (Forefront Collaborative):
    Wambui Gathirua-Mwangi’s spouse receives a salary from Lilly for work as a research scientist in dermatology.

Accreditation Statement

Forefront Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

IPMA holds accreditation with commendation from the Accreditation Council for Continuing Medical Education (ACCME) and is approved by the American Board of Medical Specialties as a Multispecialty Portfolio Provider.

Credit Designation Statement

Forefront Collaborative designates this activity for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AANP

NP: This activity is approved for 0.75 contact hour(s) of continuing education by the American Association of Nurse Practitioners. Activity ID 19103993. This activity was planned in accordance with AANP Accreditation Standards and Policies.

RN: IPMA is approved by the California Board of Registered Nursing, Provider Number 6971, for 0.75 contact hours. Each person should retain this certificate for 4 years after the course has been completed. RNs outside of California must verify with their licensing agency for approval of this course.

Instructions for Receiving Credit

Participants must complete and submit the online CME/CNE evaluation form at the conclusion of the activity and achieve a passing score of 100%. Certificates will be generated upon completion and submission of the evaluation form.

Statement of Commercial Support

This activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.

Disclaimer Statement/Disclosure of Unlabeled Use

The views and opinions expressed in this activity are those of the faculty and do not necessarily reflect the views or recommendations of Forefront Collaborative, Interstate Postgraduate Medical Association, and Lilly.

The content of this activity was independently peer reviewed by two reviewers. The reviewers of this activity have no relevant financial relationships to disclose.

This continuing medical education activity will include reference(s) to unlabeled or unapproved uses of drugs or devices.

Contact Information for Questions About the Activity

Megan_Ragan@forefrontcollab.com
317.601.4742

Activity Details

Free CME/CNE
0.75 AMA PRA Category 1 Credit(s)
0.75 Contact Hour(s)
Released: December 16, 2019
Expires: December 16, 2020
45 minutes to complete

Accredited By

 

Target Audience

Medical oncologists, community oncologists, nurse practitioners, and physician assistants. Other healthcare professionals including radiation oncologists, primary care physicians, pharmacists, and nurses who treat patients with HR+, HER2- metastatic breast cancer (mBC) may also benefit from participation in the educational activity. 

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Evaluate and apply emerging clinical data and evolving strategies for the treatment of metastatic breast cancer to optimize the outcomes of individual patients.
  • Analyze patient and disease characteristics that influence treatment selection for patients with HR+, HER2- metastatic breast cancer.

Activity Description

The treatment landscape for HR+, HER2- metastatic breast cancer has gone through a paradigm shift in treatment, with the advent of targeted therapies. From emerging clinical data to treatment selection, a multidisciplinary panel led by Hope Rugo, MD, FASCO, team up with Vandana Abramson, MD, Erika Hamilton, MD, and Lauren Czapla, NP, to provide a practical update for practicing clinicians on key treatment advances, and analyzing patient and disease characteristics influencing treatment selection for patients with HR+, HER2- metastatic breast cancer.

Statement of Educational Need

With the recent approvals, and new clinical data, medical oncologists, nurse practitioners, and physician assistants are faced with three challenges:
  • Staying abreast of the rapidly expanding evidence base to inform treatment of HR+, HER2- metastatic breast cancer (knowledge-based gaps).
  • Interpreting emerging data of approved and investigational therapies to best guide clinical decision making (competency-based gaps).
  • Analyzing patient and disease characteristics that inform treatment selection for a patient with HR+, HER2- metastatic breast cancer.

Agenda

  • Overview of HR+, HER2- emerging targeted therapies.
  • Tumor–board-style discussion of a patient with HR+, HER2- metastatic breast cancer.
  • Visual guide for treatment selection (algorithm) for HR +, HER2- metastatic breast cancer.

Faculty

Hope S. Rugo, MD, FASCO
Professor of Medicine,
Director, Breast Oncology and Clinical Trials Education
Helen Diller Family Comprehensive Cancer Center
University of California, San Francisco
San Francisco, California


Vandana G. Abramson, MD, MTR
Associate Professor of Medicine,
Division of Hematology-Oncology
Vanderbilt University Medical Center
Nashville, Tennessee


Erika P. Hamilton, MD
Director, Breast and Gynecologic Cancer Program
Sarah Cannon Research Institute/Tennessee Oncology
Nashville, Tennessee


Lauren E. Czapla, RN, MS, WHNP-BC, AOCNP
Nurse Practitioner,
Breast Oncology
Oncofertility Program
Dana-Farber Cancer Institute
Boston, Massachusetts


Conflict of Interest Policy/Disclosure Statement

Disclosure Statement
Educational activities provided by Forefront Collaborative must demonstrate balance, independence, and scientific rigor. All those in a position to control the content of an activity must disclose all relevant financial relationship(s) with commercial interest(s). The disclosures will be listed in the activity handout.

Disclosure and Conflict of Interest Resolution
Educational activities provided by Forefront Collaborative must demonstrate balance, independence, and scientific rigor. All those in a position to control the content of an activity must disclose all relevant financial relationship(s) with commercial interest(s)*. For this educational activity, all conflicts of interest have been resolved through peer review and revisions to ensure independence, evidence base, fair balance, and absence of commercial bias. Disclosures appear below.

*The ACCME defines a commercial interest as any entity producing, marketing, reselling, or distributing health care goods or services consumed by or used on patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests – unless the provider of clinical service is owned, or controlled by, an ACCME-defined commercial interest.

The following individuals have indicated that neither they nor their spouses/partners have had, in the past 12 months, financial relationship(s) with commercial interests relative to the content of this CME activity:
  • Planners (Forefront Collaborative):
    Megan Ragan
  • Faculty:
    Lauren E. Czapla, RN, MS, WHNP-BC, AOCNP
The following individuals have disclosed that they and/or their spouse/partner has had a financial relationship in the past 12 months:
  • Faculty:
    Hope S. Rugo, MD, FASCO
    Contracted research—Pfizer, Merck, Novartis, Lilly, Genentech, OBI, Odonate, Daiichi-Sankyo, Eisai, Seattle Genetics, MacroGenics, and Immunomedics (all funding to UC Regents)
    Travel support to academic meetings—Daiichi-Sankyo, Mylan, Pfizer, Amgen, Merck, AstraZeneca, MacroGenics, and Puma

    Erika P. Hamilton, MD
    Consultant—Pfizer (institutional compensation, not personal), Cascadian Therapeutics, and Lilly (institutional compensation only, not personal)
    Speakers bureau—Genentech/Roche (institutional compensation only, not personal)
    Advisory board—Lilly (institutional compensation only, not personal)
    Contracted research—Lilly, Pfizer, Genentech/Roche, Hutchison MediPharma, OncoMed, MedImmune, Stemcentrx, AbbVie, Curis, Verastem, Zymeworks, Syndax, Lycra, Rgenix, Novartis, Mersana, TapImmune, BerGenBio, Tesaro, Medivation, Kadmon, Boehringer Ingelheim, Eisai, H3 Biomedicine, Radius Health, Acerta, Takeda, MacroGenics, Immunomedics, Fujifilm, Effector, Syros, Unum, Sutro, Aravive, Deciphera, Clovis, and Sermonix

    Vandana G. Abramson, MD, MTR
    Advisory board—Novartis
    Contracted research—Novartis and Genentech

  • Planners (Forefront Collaborative):
    Wambui Gathirua-Mwangi’s spouse receives a salary from Lilly for work as a research scientist in dermatology.

Accreditation Statement

Forefront Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

IPMA holds accreditation with commendation from the Accreditation Council for Continuing Medical Education (ACCME) and is approved by the American Board of Medical Specialties as a Multispecialty Portfolio Provider.

Credit Designation Statement

Forefront Collaborative designates this activity for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AANP

NP: This activity is approved for 0.75 contact hour(s) of continuing education by the American Association of Nurse Practitioners. Activity ID 19103993. This activity was planned in accordance with AANP Accreditation Standards and Policies.

RN: IPMA is approved by the California Board of Registered Nursing, Provider Number 6971, for 0.75 contact hours. Each person should retain this certificate for 4 years after the course has been completed. RNs outside of California must verify with their licensing agency for approval of this course.

Instructions for Receiving Credit

Participants must complete and submit the online CME/CNE evaluation form at the conclusion of the activity and achieve a passing score of 100%. Certificates will be generated upon completion and submission of the evaluation form.

Statement of Commercial Support

This activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.

Disclaimer Statement/Disclosure of Unlabeled Use

The views and opinions expressed in this activity are those of the faculty and do not necessarily reflect the views or recommendations of Forefront Collaborative, Interstate Postgraduate Medical Association, and Lilly.

The content of this activity was independently peer reviewed by two reviewers. The reviewers of this activity have no relevant financial relationships to disclose.

This continuing medical education activity will include reference(s) to unlabeled or unapproved uses of drugs or devices.

Contact Information for Questions About the Activity

Megan_Ragan@forefrontcollab.com
317.601.4742

0.50 CME / CNE
Forefront Collaborative
HER Disease, Shared Decisions: Engaging the patient when choosing HR+, HER2- metastatic breast cancer treatment options

HER Disease, Shared Decisions: Engaging the patient when choosing HR+, HER2- metastatic breast cancer treatment options

Start

Activity Details

Free CME/CNE
0.5 AMA PRA Category 1 Credit(s)
0.5 Contact Hour(s)
Released: December 16, 2019
Expires: December 16, 2020
30 minutes to complete

Accredited By

 

Target Audience

Medical oncologists, community oncologists, nurse practitioners, and physician assistants. Other healthcare professionals such as radiation oncologists, primary care physicians, pharmacists, and nurses who treat patients with HR+, HER2- metastatic breast cancer (mBC) may benefit from participation in the proposed educational activities. 

Learning Objectives

  • Upon completion of this activity, participants should be able to:
    • Engage patients with HR+ HER2- mBC in a shared decision making (SDM) process on the goals of treatment, treatment plan development, and treatment modification.
    • Identify strategies to enhance symptom management and increase adherence to treatment.

Activity Description

The advent of CDK4/6 inhibitors as effective treatment for mBC is a great milestone for patients with mBC but requires a deep understanding of the benefits and risks of the treatment options. From SDM simulation to symptom management, breast cancer specialists, Erika Hamilton, MD, and Lauren Czapla, NP, team up to provide a practical update for integrating SDM in practice and strategies to enhance symptom management and increase adherence.

Statement of Educational Need

Cancer treatment decision making is challenging because there are multiple effective therapies that are interconnected, with a complex interplay between their benefits and risks. SDM is a best practice health care process used to help patients but is not fully integrated in breast cancer care.

Agenda

  • Overview of SDM to improve treatment adherence and patient outcomes.
  • Simulation of SDM with a patient with HR+, HER2- mBC.
  • Overview of strategies to enhance symptom management and increase adherence to treatment.

Faculty

Erika P. Hamilton, MD
Director, Breast and Gynecologic Cancer Program
Sarah Cannon Research Institute/Tennessee Oncology
Nashville, Tennessee


Lauren E. Czapla, RN, MS, WHNP-BC, AOCNP
Nurse Practitioner,
Breast Oncology
Oncofertility Program
Dana-Farber Cancer Institute
Boston, Massachusetts


Conflict of Interest Policy/Disclosure Statement

Disclosure Statement
Educational activities provided by Forefront Collaborative must demonstrate balance, independence, and scientific rigor. All those in a position to control the content of an activity must disclose all relevant financial relationship(s) with commercial interest(s). The disclosures will be listed in the activity handout.

Disclosure and Conflict of Interest Resolution
Educational activities provided by Forefront Collaborative must demonstrate balance, independence, and scientific rigor. All those in a position to control the content of an activity must disclose all relevant financial relationship(s) with commercial interest(s)*. For this educational activity, all conflicts of interest have been resolved through peer review and revisions to ensure independence, evidence base, fair balance, and absence of commercial bias. Disclosures appear below.

*The ACCME defines a commercial interest as any entity producing, marketing, reselling, or distributing health care goods or services consumed by or used on patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests – unless the provider of clinical service is owned, or controlled by, an ACCME-defined commercial interest.

The following individuals have indicated that neither they nor their spouses/partners have had, in the past 12 months, financial relationship(s) with commercial interests relative to the content of this CME activity:

  • Planners (Forefront Collaborative):
    Megan Ragan
  • Faculty:
    Lauren E. Czapla, RN, MS, WHNP-BC, AOCNP
The following individuals have disclosed that they and/or their spouse/partner has had a financial relationship in the past 12 months:
  • Faculty:
    Erika P. Hamilton, MD
    • Consultant—Pfizer (institutional compensation, not personal), Cascadian Therapeutics, and Lilly (institutional compensation only, not personal)
      Speakers bureau—Genentech/Roche (institutional compensation only, not personal)
      Advisory board—Lilly (institutional compensation only, not personal)
      Contracted research—Lilly, Pfizer, Genentech/Roche, Hutchison MediPharma, OncoMed, MedImmune, Stemcentrx, AbbVie, Curis, Verastem, Zymeworks, Syndax, Lycra, Rgenix, Novartis, Mersana, TapImmune, BerGenBio, Tesaro, Medivation, Kadmon, Boehringer Ingelheim, Eisai, H3 Biomedicine, Radius Health, Acerta, Takeda, MacroGenics, Immunomedics, Fujifilm, Effector, Syros, Unum, Sutro, Aravive, Deciphera, Clovis, and Sermonix

  • Planners (Forefront Collaborative):
    Wambui Gathirua-Mwangi’s spouse receives a salary from Lilly for work as a research scientist in dermatology.

Accreditation Statement

Forefront Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

IPMA holds accreditation with commendation from the Accreditation Council for Continuing Medical Education (ACCME) and is approved by the American Board of Medical Specialties as a Multispecialty Portfolio Provider.

Credit Designation Statement

Forefront Collaborative designates this activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AANP

NP: This activity is approved for 0.5 contact hour(s) of continuing education by the American Association of Nurse Practitioners. Activity ID 19103994. This activity was planned in accordance with AANP Accreditation Standards and Policies.

RN: IPMA is approved by the California Board of Registered Nursing, Provider Number 6971, for 0.5 contact hours. Each person should retain this certificate for 4 years after the course has been completed. RNs outside of California must verify with their licensing agency for approval of this course.

Instructions for Receiving Credit

Participants must complete and submit the online CME evaluation form at the conclusion of the activity and achieve a passing score of 100%. Certificates will be generated upon completion and submission of the evaluation form.

Statement of Commercial Support

This activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.

Disclaimer Statement/Disclosure of Unlabeled Use

The views and opinions expressed in this activity are those of the faculty and do not necessarily reflect the views or recommendations of Forefront Collaborative, Interstate Postgraduate Medical Association, and Lilly.

The content of this activity was independently peer reviewed by two reviewers. The reviewers of this activity have no relevant financial relationships to disclose.

This continuing medical education activity will include reference(s) to unlabeled or unapproved uses of drugs or devices.

Contact Information for Questions About the Activity

Megan_Ragan@forefrontcollab.com
317.601.4742

Activity Details

Free CME/CNE
0.5 AMA PRA Category 1 Credit(s)
0.5 Contact Hour(s)
Released: December 16, 2019
Expires: December 16, 2020
30 minutes to complete

Accredited By

 

Target Audience

Medical oncologists, community oncologists, nurse practitioners, and physician assistants. Other healthcare professionals such as radiation oncologists, primary care physicians, pharmacists, and nurses who treat patients with HR+, HER2- metastatic breast cancer (mBC) may benefit from participation in the proposed educational activities. 

Learning Objectives

  • Upon completion of this activity, participants should be able to:
    • Engage patients with HR+ HER2- mBC in a shared decision making (SDM) process on the goals of treatment, treatment plan development, and treatment modification.
    • Identify strategies to enhance symptom management and increase adherence to treatment.

Activity Description

The advent of CDK4/6 inhibitors as effective treatment for mBC is a great milestone for patients with mBC but requires a deep understanding of the benefits and risks of the treatment options. From SDM simulation to symptom management, breast cancer specialists, Erika Hamilton, MD, and Lauren Czapla, NP, team up to provide a practical update for integrating SDM in practice and strategies to enhance symptom management and increase adherence.

Statement of Educational Need

Cancer treatment decision making is challenging because there are multiple effective therapies that are interconnected, with a complex interplay between their benefits and risks. SDM is a best practice health care process used to help patients but is not fully integrated in breast cancer care.

Agenda

  • Overview of SDM to improve treatment adherence and patient outcomes.
  • Simulation of SDM with a patient with HR+, HER2- mBC.
  • Overview of strategies to enhance symptom management and increase adherence to treatment.

Faculty

Erika P. Hamilton, MD
Director, Breast and Gynecologic Cancer Program
Sarah Cannon Research Institute/Tennessee Oncology
Nashville, Tennessee


Lauren E. Czapla, RN, MS, WHNP-BC, AOCNP
Nurse Practitioner,
Breast Oncology
Oncofertility Program
Dana-Farber Cancer Institute
Boston, Massachusetts


Conflict of Interest Policy/Disclosure Statement

Disclosure Statement
Educational activities provided by Forefront Collaborative must demonstrate balance, independence, and scientific rigor. All those in a position to control the content of an activity must disclose all relevant financial relationship(s) with commercial interest(s). The disclosures will be listed in the activity handout.

Disclosure and Conflict of Interest Resolution
Educational activities provided by Forefront Collaborative must demonstrate balance, independence, and scientific rigor. All those in a position to control the content of an activity must disclose all relevant financial relationship(s) with commercial interest(s)*. For this educational activity, all conflicts of interest have been resolved through peer review and revisions to ensure independence, evidence base, fair balance, and absence of commercial bias. Disclosures appear below.

*The ACCME defines a commercial interest as any entity producing, marketing, reselling, or distributing health care goods or services consumed by or used on patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests – unless the provider of clinical service is owned, or controlled by, an ACCME-defined commercial interest.

The following individuals have indicated that neither they nor their spouses/partners have had, in the past 12 months, financial relationship(s) with commercial interests relative to the content of this CME activity:

  • Planners (Forefront Collaborative):
    Megan Ragan
  • Faculty:
    Lauren E. Czapla, RN, MS, WHNP-BC, AOCNP
The following individuals have disclosed that they and/or their spouse/partner has had a financial relationship in the past 12 months:
  • Faculty:
    Erika P. Hamilton, MD
    • Consultant—Pfizer (institutional compensation, not personal), Cascadian Therapeutics, and Lilly (institutional compensation only, not personal)
      Speakers bureau—Genentech/Roche (institutional compensation only, not personal)
      Advisory board—Lilly (institutional compensation only, not personal)
      Contracted research—Lilly, Pfizer, Genentech/Roche, Hutchison MediPharma, OncoMed, MedImmune, Stemcentrx, AbbVie, Curis, Verastem, Zymeworks, Syndax, Lycra, Rgenix, Novartis, Mersana, TapImmune, BerGenBio, Tesaro, Medivation, Kadmon, Boehringer Ingelheim, Eisai, H3 Biomedicine, Radius Health, Acerta, Takeda, MacroGenics, Immunomedics, Fujifilm, Effector, Syros, Unum, Sutro, Aravive, Deciphera, Clovis, and Sermonix

  • Planners (Forefront Collaborative):
    Wambui Gathirua-Mwangi’s spouse receives a salary from Lilly for work as a research scientist in dermatology.

Accreditation Statement

Forefront Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

IPMA holds accreditation with commendation from the Accreditation Council for Continuing Medical Education (ACCME) and is approved by the American Board of Medical Specialties as a Multispecialty Portfolio Provider.

Credit Designation Statement

Forefront Collaborative designates this activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AANP

NP: This activity is approved for 0.5 contact hour(s) of continuing education by the American Association of Nurse Practitioners. Activity ID 19103994. This activity was planned in accordance with AANP Accreditation Standards and Policies.

RN: IPMA is approved by the California Board of Registered Nursing, Provider Number 6971, for 0.5 contact hours. Each person should retain this certificate for 4 years after the course has been completed. RNs outside of California must verify with their licensing agency for approval of this course.

Instructions for Receiving Credit

Participants must complete and submit the online CME evaluation form at the conclusion of the activity and achieve a passing score of 100%. Certificates will be generated upon completion and submission of the evaluation form.

Statement of Commercial Support

This activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.

Disclaimer Statement/Disclosure of Unlabeled Use

The views and opinions expressed in this activity are those of the faculty and do not necessarily reflect the views or recommendations of Forefront Collaborative, Interstate Postgraduate Medical Association, and Lilly.

The content of this activity was independently peer reviewed by two reviewers. The reviewers of this activity have no relevant financial relationships to disclose.

This continuing medical education activity will include reference(s) to unlabeled or unapproved uses of drugs or devices.

Contact Information for Questions About the Activity

Megan_Ragan@forefrontcollab.com
317.601.4742

1.00 CME / CNE / CPE
Rush University Medical Center
Evolving Strategies for Using CDK 4/6 Inhibitors in the Treatment of HR+ (HER2-) Advanced Breast Cancer

Evolving Strategies for Using CDK 4/6 Inhibitors in the Treatment of HR+ (HER2-) Advanced Breast Cancer

Start

Activity Details

Free CME/CNE/CPE
1.0 AMA PRA Category 1 Credit(s)
1.0 Contact Hour(s)
1 hour to complete

Accredited by

Rush University Medical Center

Co-provided by

Target Audience

This activity is designed to meet the educational needs of hematologists, hematologists/oncologists, community oncologists, oncology nurses and NPs, pharmacists and other healthcare professionals involved in the treatment of patients with breast cancer.

Learning Objectives

After completing this program, participants should be able to:

  1. Evaluate recent clinical trial data for CDK4/6 inhibitors currently approved for first-line treatment of advanced breast cancer
  2. Select appropriate first-line therapy for patients with HR+ (Her2-) advanced breast cancer on the basis of patient and disease characteristics
  3. Develop strategies for the management of adverse events associated with CDK4/6 inhibitor therapy

Activity Description

This educational activity is designed to provide the hematology/oncology care team with the latest developments and critical insights into the management of breast cancer. This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness and application.

Statement of Educational Need

Taking into consideration the continued evolution of therapeutic modalities and management strategies for breast cancer along with the information burden placed on busy healthcare professionals, expert guidance and interpretation of the clinical significance of emerging clinical data will benefit those caring for patients with breast cancer, allowing for ease of assessment and incorporation into clinical practice.

Faculty

Rita Nanda, MD
Associate Professor of Medicine
Director, Breast Oncology Program
University of Chicago
Chicago, IL


Conflict of Interest Policy/Disclosure Statement

Rita Nanda, MD, Disclosures:
Research Grant from AstraZeneca, Celgene, Corcept Therapeutics, Genentech/Roche, Immunomedics, Merck, Odonate Therapeutics, Pfizer, Seattle Genetics.
Consultant to Aduro, AstraZeneca, Athenex, Celgene, Daiichi Sankyo Inc., Genentech, MacroGenics, Merck, Novartis, Pfizer, Puma, Syndax.
G1Theraputics (DSMB); OBI Pharma (Clinical Steering Committee)

Accreditation Statement

In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This activity is being presented without bias and with commercial support.

Rush University Medical Center designates this enduring activity for a maximum of one (1) AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Rush University Medical Center designates this enduring activity for a maximum of one (1) continuing nursing education credit(s).

Rush University Medical Center designates this enduring activity for a maximum of one (1) continuing education unit(s) in Pharmacy.

Instructions for Receiving Credit

In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.

Statement of Commercial Support

This activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding visit www.lillygrantoffice.com.

Disclaimer Statement/Disclosure of Unlabeled Use

Rush University and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

Contact Information for Questions about the Activity

info@plexuscomm.com

Activity Details

Free CME/CNE/CPE
1.0 AMA PRA Category 1 Credit(s)
1.0 Contact Hour(s)
1 hour to complete

Accredited by

Rush University Medical Center

Co-provided by

Target Audience

This activity is designed to meet the educational needs of hematologists, hematologists/oncologists, community oncologists, oncology nurses and NPs, pharmacists and other healthcare professionals involved in the treatment of patients with breast cancer.

Learning Objectives

After completing this program, participants should be able to:

  1. Evaluate recent clinical trial data for CDK4/6 inhibitors currently approved for first-line treatment of advanced breast cancer
  2. Select appropriate first-line therapy for patients with HR+ (Her2-) advanced breast cancer on the basis of patient and disease characteristics
  3. Develop strategies for the management of adverse events associated with CDK4/6 inhibitor therapy

Activity Description

This educational activity is designed to provide the hematology/oncology care team with the latest developments and critical insights into the management of breast cancer. This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness and application.

Statement of Educational Need

Taking into consideration the continued evolution of therapeutic modalities and management strategies for breast cancer along with the information burden placed on busy healthcare professionals, expert guidance and interpretation of the clinical significance of emerging clinical data will benefit those caring for patients with breast cancer, allowing for ease of assessment and incorporation into clinical practice.

Faculty

Rita Nanda, MD
Associate Professor of Medicine
Director, Breast Oncology Program
University of Chicago
Chicago, IL


Conflict of Interest Policy/Disclosure Statement

Rita Nanda, MD, Disclosures:
Research Grant from AstraZeneca, Celgene, Corcept Therapeutics, Genentech/Roche, Immunomedics, Merck, Odonate Therapeutics, Pfizer, Seattle Genetics.
Consultant to Aduro, AstraZeneca, Athenex, Celgene, Daiichi Sankyo Inc., Genentech, MacroGenics, Merck, Novartis, Pfizer, Puma, Syndax.
G1Theraputics (DSMB); OBI Pharma (Clinical Steering Committee)

Accreditation Statement

In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This activity is being presented without bias and with commercial support.

Rush University Medical Center designates this enduring activity for a maximum of one (1) AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Rush University Medical Center designates this enduring activity for a maximum of one (1) continuing nursing education credit(s).

Rush University Medical Center designates this enduring activity for a maximum of one (1) continuing education unit(s) in Pharmacy.

Instructions for Receiving Credit

In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.

Statement of Commercial Support

This activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding visit www.lillygrantoffice.com.

Disclaimer Statement/Disclosure of Unlabeled Use

Rush University and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

Contact Information for Questions about the Activity

info@plexuscomm.com

0.75 CME
Vindico
Optimizing the Use of Screening and Imaging in Women With Dense Breasts

Optimizing the Use of Screening and Imaging in Women With Dense Breasts

Start

Activity Details

Free CME
0.75 AMA PRA Category 1 Credit(s)
Released: November 26, 2019
Expires: November 25, 2020
45 minutes to complete

This activity has been updated to include additional resources. Please check the educational tools section of this activity to access the additional resources.

Accredited By

This continuing medical education activity is provided by

Endorsed by

Target Audience

The intended audience for the activity is radiologists, obstetrician-gynecologists, primary care physicians and other health care professionals involved in imaging, or referral for imaging, of patients with dense breasts.

Learning Objectives

Upon successful completion of the activity, participants should be better able to:

  • Review the effects that dense breasts have on cancer risk, as well as their effect on the interpretation of imaging results used in diagnosis and screening.
  • Summarize evidence-based classification criteria used to measure breast density.
  • Determine when it is appropriate to use advanced imaging in patients with dense breasts.
  • Assess the safety of gadolinium-based contrast agents for use in advanced magnetic resonance imaging.
  • Evaluate processes and procedures that can improve the ordering of conventional and advanced imaging for women with dense breasts.
  • Incorporate processes that improve the multidisciplinary management of patients with dense breasts that are undergoing screening or diagnostic follow-up.

Activity Description

Screening mammography has remained the most useful tool for breast cancer detection and has consistently demonstrated a reduction in breast cancer mortality. Dense breast tissue absorbs significantly more radiation during mammography than fatty breast tissue, reducing the accuracy of mammography in women with this condition. However, other imaging modalities exist to increase the accuracy of detecting cancer in dense breast tissue. In this continuing medical education panel discussion, expert physicians from multiple fields will explore alternative imaging modalities for examining breast tissue, in addition to mammography, to diagnose breast cancer in women.

Faculty

Activity Chair:
Deepa Sheth, MD
Assistant Professor of Radiology
Breast Imaging Center
University of Chicago Medicine
Chicago, IL
  • Disclosure: No relevant financial relationships to disclose.


Faculty:
Susan Hong, MD, MPH
Director of Cancer Survivorship
Associate Professor of Medicine and Surgery
University of Illinois
Chicago, IL
  • Disclosure: No relevant financial relationships to disclose.


Iris Romero, MD, MS
Associate Professor
Department of Ob/Gyn
University of Chicago Medicine
Chicago, IL
  • Disclosure: No relevant financial relationships to disclose.


Reviewer:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
  • Disclosure: No relevant financial relationships to disclose.
Vindico Medical Education Staff:
  • Disclosure: No relevant financial relationships to disclose.

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Relationship information appears above.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Guerbet LLC.

Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of FDA-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage.

Disclaimer

The material presented at or in any Vindico Medical Education continuing education activity does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education, nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2019 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Activity Details

Free CME
0.75 AMA PRA Category 1 Credit(s)
Released: November 26, 2019
Expires: November 25, 2020
45 minutes to complete

This activity has been updated to include additional resources. Please check the educational tools section of this activity to access the additional resources.

Accredited By

This continuing medical education activity is provided by

Endorsed by

Target Audience

The intended audience for the activity is radiologists, obstetrician-gynecologists, primary care physicians and other health care professionals involved in imaging, or referral for imaging, of patients with dense breasts.

Learning Objectives

Upon successful completion of the activity, participants should be better able to:

  • Review the effects that dense breasts have on cancer risk, as well as their effect on the interpretation of imaging results used in diagnosis and screening.
  • Summarize evidence-based classification criteria used to measure breast density.
  • Determine when it is appropriate to use advanced imaging in patients with dense breasts.
  • Assess the safety of gadolinium-based contrast agents for use in advanced magnetic resonance imaging.
  • Evaluate processes and procedures that can improve the ordering of conventional and advanced imaging for women with dense breasts.
  • Incorporate processes that improve the multidisciplinary management of patients with dense breasts that are undergoing screening or diagnostic follow-up.

Activity Description

Screening mammography has remained the most useful tool for breast cancer detection and has consistently demonstrated a reduction in breast cancer mortality. Dense breast tissue absorbs significantly more radiation during mammography than fatty breast tissue, reducing the accuracy of mammography in women with this condition. However, other imaging modalities exist to increase the accuracy of detecting cancer in dense breast tissue. In this continuing medical education panel discussion, expert physicians from multiple fields will explore alternative imaging modalities for examining breast tissue, in addition to mammography, to diagnose breast cancer in women.

Faculty

Activity Chair:
Deepa Sheth, MD
Assistant Professor of Radiology
Breast Imaging Center
University of Chicago Medicine
Chicago, IL
  • Disclosure: No relevant financial relationships to disclose.


Faculty:
Susan Hong, MD, MPH
Director of Cancer Survivorship
Associate Professor of Medicine and Surgery
University of Illinois
Chicago, IL
  • Disclosure: No relevant financial relationships to disclose.


Iris Romero, MD, MS
Associate Professor
Department of Ob/Gyn
University of Chicago Medicine
Chicago, IL
  • Disclosure: No relevant financial relationships to disclose.


Reviewer:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
  • Disclosure: No relevant financial relationships to disclose.
Vindico Medical Education Staff:
  • Disclosure: No relevant financial relationships to disclose.

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Relationship information appears above.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Guerbet LLC.

Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of FDA-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage.

Disclaimer

The material presented at or in any Vindico Medical Education continuing education activity does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education, nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2019 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com